Assessment of Origanum Vulgaris L. Effect on Allergic Rhinitis Compared to Placebo: a randomized-controlled clinical trial.

Shiraz University of Medical Sciences0 个研究点目标入组 110 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•men and women aged 18 to 60 years old; outpatients with a history or diagnosis of allergic rhinitis for at least 6 months before the first visit; allergic rhinitis and the numbers of eosinophil in the nasal mucous or the skin Prick test is proven (if not already done during the last 6 months); signing informed consent; patients with a diagnosis of allergic rhinitis are previous topical or systemic treatments include antihistamines and corticosteroids have not responded or those with complications who have had previous with these drugs, do not want or cannot be treated with these drugs are; no anatomical abnormalities in the nose (nasal polyp or severe deviation); drugs that are used to treat allergies and if they use, it must be discontinued before the study; patients who are able to read and understand the consent form; ; patients who have not dementia; are not pregnant or are able to communicate and patients without nasopharyngeal tumors; patients who have not a history of drug allergy with Origanum vulgare.
•Exclusion criteria: patients taking drugs other than drugs that must consume according to the research plan, the duration of the project will be excluded from use; patients during the study have a fungal, viral or bacterial disease; patients who do not follow the recommended instructions will be excluded.

发起方